Vopec Pharmaceuticals has received the NOC (no objection certificate) and license to develop and test its new anti cancer drug as a new chemical entity (NCE), which also offers a promising therapeutic option for COVID-19.
It inhibits Angiotensin-converting enzyme-2 (ACE-2) and Nonstructural protein-15 (Nsp-15). The NCE, according to the company, has the ability to target lungs to eliminate cancer stem cells (CSCs) and also treat COVID-19 infection.
The DCGI approval also includes testing and analysis of the NCE. The company also applied for a US patent for the same.
“We would approach DCGI to conduct the required bioequivalence clinical trials in India and also seek strategic private investments or government aid to commercialize this product, subject to all regulatory approvals and trials. We are being represented by Cooley Group, one of the foremost leading Pharma Attorneys in the US, for the patent approval,” Ramakrishnan Karnan, director, Vopec Pharmaceuticals told Pharmabiz.